



To: Members of the Governing Board

From: Jonathan Y. Thomas, Chair, and Art Torres, Vice Chair

Re: Appointments to the AAWG

As you know, Proposition 14 created the Treatments and Cures Accessibility and Affordability Working Group (AAWG) to recommend policies and programs to the Board to enhance access to, and the affordability of, treatments and cures arising from CIRM-funded research for California patients. The AAWG is composed of 17 members: seven members of the Board, including the Chair and Vice Chair, and 10 outside experts. Pursuant to Health & Safety Code section 125290.75, the Chair and Vice Chair of the Board are required to nominate members of the AAWG for approval by the Board. To date, the Board has appointed the following Board members to the AAWG: Dan Bernal, Allison Brashear, David Higgins, Adrianna Padilla, Al Rowlett.

In addition, the Board appointed:

- James DeBenedetti, the Director of Plan Management at Covered California, who fills the seat for an expert in California's public insurance program.
- Dana Dornsife, the founder of Lazerex Cancer Foundation, who fills the seat for representative from a philanthropic organization who has experience assisting patients with clinical trial access and affordability, or with access to, and the affordability of, innovative therapies.
- Dana Goldman, Interim Dean of the USC Sol Price School of Public Policy, where he holds the Leonard Schaeffer Chair and is a Distinguished Professor of Public Policy, Pharmacy, and Economics to fill the seat for a health care economist, with experience in advising or negotiating with private insurers, government insurers, or corporate self-insurance programs on coverage for innovative therapies or human trials, including experience in assisting hospitals and clinics in covering financial gaps in coverage of the direct and indirect costs of innovative therapies.

We now wish to nominate:

1999 Harrison Street, Suite 1650, Oakland, CA 94612



- Ann Boynton, Executive Director, Strategic Planning at the UC Davis Medical Center who fills the seat for a representative from hospitals in California that are participating in stem cell clinical trials or FDA approved stem cell or genetic therapy.
- Adrienne Shapiro, Patient Advocate for Sickle Cell Disease, who fills the seat for a representative from a patient advocacy organization who has technical expertise or experience in coverage, qualifications, and the process for reimbursement of innovative therapies.
- Ammar Qadan, Vice President and Global Head of Market Access - Illumina Inc. who fills the seat for an expert or a highly knowledgeable individual with experience in federal therapy coverage, qualifications, and process for reimbursement, including, if possible, experience with the Centers for Medicare and Medicaid Services.

Their bios are attached.

**Ann Boynton**  
**Executive Director, Strategic Planning**  
**UC Davis Medical Center**  
**alboynton@ucdavis.edu**

As Executive Director, Strategic Planning, Ms. Boynton is responsible for the development and periodic refinement of the enterprise strategic plan and departmental strategic operating plans, continual strategic market surveillance, payor and governmental strategies, and strategic facilitation for the enterprise. Prior to this role, she was the Director of Care Services and Innovation, overseeing value-based contract implementation and payor strategies, population health program development and total cost of care contract management. She served as Deputy Executive Officer of Benefit Programs, Policy and Planning for the California Public Employees' Retirement System, providing executive leadership for the health benefit program, including health plan benefit design and development, and health plan negotiations. Her scope included purchasing health care for more than 1.3 million California active and retired public employees with a portfolio of more than \$6 billion annually and management of long term care insurance for more than 160,000 individuals. She served as Undersecretary at the California Health and Human Services Agency where she provided policy and programmatic oversight to 13 state departments including the Departments of Health Care Services, Public Health, Social Services and Mental Health, among others. She also served as Governor Arnold Schwarzenegger's Chief Deputy Cabinet Secretary. Her experience includes almost twenty years as a management consultant in the private sector, including employment with IBM and PricewaterhouseCoopers, and owning her own management consulting business.

Adrienne Bell-Cors Shapiro is a Sickle Cell Disease and stem cell Patient Advocate, the Founder and Science Administrator of the Axis Advocacy foundation, and a fifth generation mother of a child with Sickle Cell Disease.

She is a recipient of the highest honor in the regenerative medicine community, the 2018 Stem Cell and Regenerative Medicine Action Inspiration Award. She was one of the first supporters of the work done by UCLA'S Dr. Don Kohn in bone marrow and later stem cell transplants. As a firm believer that stem cell science will cure Sickle Cell Disease, she has dedicated a large portion of her life to improving the lives and overall healthcare of those living with the disease.

In the past four years Ms. Shapiro has found her voice as a stem cell activist, speaking at multiple forums in support of the funding for clinical trials through the California Institute for Regenerative Medicine (CIRM).

Adrienne is a member of several CIRM Clinical Advisory Panels (CAP) for Stem Cell Clinical Trials as the Sickle Cell Disease Advocate. A role that allows her to have input throughout the clinical trial process. She is an ambassador for the Americans for Cures Foundation. Adrienne is also on patient advisory panels for the FDA, ASH, NASEM, AMA and the NIH Heart Lung & Blood. Her experience includes attending educational conferences and seminars, as well as meeting with lawmakers to promote support for the Sickle Cell Community. She is on the steering committee of The Cure Sickle Cell Initiative. Adrienne is on the board of several advocacy groups including Sick Cells and The California Chronic Care Coalition. She is a member of the FDA Patient Engagement Collaborative (PEC) and a member of the steering committee of the Paradigm Project for Academy Health.

Adrienne believes stem cell science will be the answer. However, until we have a cure for Sickle Cell Disease, pain is a fact of the illness and humane treatment and support is required. Thus, Adrienne and Axis Advocacy are dedicated to supporting scientists, researchers and care providers as well as patients, caregivers and their families.

Ammar Qadan, BSc. Pharm

Vice President and Global Head of Market Access - Illumina Inc.

Ammar Qadan is Vice President and Global Market Access Lead at Illumina, responsible for Health Economics & Outcomes Research, Market Access/Pricing Strategy, Field Market Access, Payer Policy, and Advocacy.

Ammar has built his career around partnership and patient-focused innovation and in particular, around value and affordability. For example, at Illumina he led the design and execution of a first-ever risk-sharing agreement with Harvard Pilgrim Healthcare (HPHC) to dramatically expand access to a cutting-edge women's health screening technology – and, uniquely in such arrangements, published the results. Based on that success, he just led a second value-based arrangement with HPHC, this time for Illumina's whole genome sequencing program in children.

Ammar's focus on value began when he started his career at Bristol Myers Squibb (BMS). He worked in six different countries, learning to navigate and find patient-affordability solutions within widely varying healthcare systems, ranging from single-payer governments to those with little or no reimbursement at all. In 2014 he joined Halozyme Therapeutics as Vice President and Global Product Team Lead where he was instrumental in revamping the company's biomarker-driven oncology program strategy, leading to new clinical development programs and major partnerships.

Ammar has worked in nearly a dozen therapeutic categories, from oncology and virology to cardiovascular and diabetes, at virtually all product stages. And he's done so in a variety of functions – sales, marketing, and clinical development, as well as market access. Ammar has been a speaker and panelist on value-based healthcare at many conferences, including BIO 2020

A pharmacist by training, Ammar is married to another pharmacist, Reewa Nazzal, and has two children, Nasser and Yara. He serves on boards of two civil-liberties organizations in San Diego, where he lives.